Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

por Oliva, Stefania, Bruinink, Davine Hofste op, Rihova, Lucie, D’Agostino, Mattia, Pantani, Lucia, Capra, Andrea, van der Holt, Bronno, Troia, Rossella, Petrucci, Maria Teresa, Villanova, Tania, Vsianska, Pavla, Jugooa, Romana, Brandt-Hagens, Claudia, Gilestro, Milena, Offidani, Massimo, Ribolla, Rossella, Galli, Monica, Hajek, Roman, Gay, Francesca, Cavo, Michele, Omedé, Paola, van der Velden, Vincent H. J., Boccadoro, Mario, Sonneveld, Pieter
Publicado 2021